ArticleHellenic urology2025
A narrative review of the current state of circulating tumor cells in prostate cancer diagnostic.
Article in Hellenic urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research protocol for the evaluation of TriNetra™ prostate: a circulating tumor cell-based diagnostic tool for prostate cancer.International journal of surgery protocols · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Circulating tumor cells (CTCs) in prostate cancer (PCa) have been an area of interest over the past 35 years. The aim of this narrative review is to summarize data on CTC application in PCa diagnosis. Several CTC detection tools have been developed; however, most of them only assess subpopulations expressing matching biomarkers. Thus, a combined detection system might be useful, and priority should be given to creating a universal panel that covers a broad spectrum of PCa subtypes. Expression of CD82 and several other markers carries prognostic value and correlates with stage and relapse risk. In metastatic PCa, CTC detection correlates with both survival and response to therapy. AR-V7 expression by CTCs is associated with resistance to androgen receptor signaling inhibitors (ARSis), while the response to taxanes remains unaffected. OCT4 expression in CTCs is associated with higher serum LDH levels, worse radiographic progression-free survival, and overall survival. Ezrin overexpression in CTCs is associated with bone metastasis in PCa patients. HER2-positive CTC detection correlates with worse overall and progression-free survival among patients treated with ARSis. Prostate-specific membrane antigen (PSMA) expression in CTCs was associated with metastases, lower overall survival and progression-free survival, as well as poor response to chemotherapy in mCRPCa. Overall, CTC detection for PCa screening, early diagnosis, and prognosis in localized disease offers limited added value. Conversely, in metastatic PCa it shows promising results as a prognostic marker. AR-V7 expression by CTCs is a predictor of response to ARS inhibitors, while PSMA expression in CTCs is associated with metastases, poor prognosis, and suboptimal treatment response. OCT4, HER2, and ezrin in CTCs were also predictors of poor prognosis and treatment response, but the data is limited. If explored further, microRNAs could serve as a potential alternative to circulating tumor cells, as they are - in theory - able to perform the same functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.